Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.47% | 3.55% | 4.54% | 22.78% | -30.39% |
| Total Depreciation and Amortization | -13.26% | 1.50% | 2.10% | -70.53% | 3,940.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.38% | 600.00% | -204.79% | -90.37% | 347.48% |
| Change in Net Operating Assets | 228.06% | -271.98% | 452.68% | -94.74% | 243.64% |
| Cash from Operations | 38.93% | -16.12% | 10.02% | -10.17% | 28.85% |
| Capital Expenditure | 100.00% | -- | 100.00% | 61.29% | -3.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -128.74% | 65.01% | 10.88% | -6.08% | 404.87% |
| Cash from Investing | -128.74% | 64.99% | 10.93% | -6.03% | 406.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -31.45% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -45.82% | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 1,100.00% | -101.08% | 896.43% | 104.17% | -514.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -270.38% | 836.27% | 72.10% | -91.57% | 87.86% |